Table 2.
The distribution of patients by estimated glomerular filtration status based upon initiation of therapy with a glucagon-like peptide-1 receptor agonist therapy or any other glucose-lowering agent
| Patient characteristics | eGFR (mL/min/1.73 m2) | |||||
|---|---|---|---|---|---|---|
| ≥ 90 | < 90 and ≥ 60 | < 60 and ≥ 45 | < 45 and ≥ 30 | < 30 and ≥ 15 | < 15 | |
| Sample size | 14,506 (36.0) | 17,034 (42.3) | 5114 (12.7) | 2608 (6.5) | 843 (2.1) | 194 (0.5) |
| Index therapy a | ||||||
| GLP-1 RA | 1425 (9.8) | 1183 (6.9) | 383 (7.5) | 179 (6.9) | 48 (5.7) | 7 (3.6) |
| Other GLA | 13,081 (90.2) | 15,851 (93.1) | 4731 (92.5) | 2429 (93.1) | 795 (94.3) | 187 (96.4) |
| Other GLA—by index class(es) | ||||||
| Basal Insulin | 815 (5.6) | 1042 (6.1) | 443 (8.7) | 391 (15.0) | 179 (21.2) | 59 (30.4) |
| Basal insulin + bolus insulin | –b | –b | 110 (2.2) | 80 (3.1) | 47 (5.6) | 19 (9.8) |
| Bolus insulin | 279 (1.9) | 381 (2.2) | 194 (3.8) | 175 (6.7) | 72 (8.5) | 23 (11.9) |
| DPP-4 | 963 (6.6) | 1331 (7.8) | 618 (12.1) | 472 (18.1) | 149 (17.7) | 25 (12.9) |
| Metformin | 6686 (46.1) | 8079 (47.4) | 1738 (34.0) | 499 (19.1) | 39 (4.6) | 4 (2.1) |
| Metformin + sulfonylurea | 424 (2.9) | 396 (2.3) | 101 (2.0) | –b | –b | –b |
| Oral fixed combination | 1135 (7.8) | 1182 (6.9) | 264 (5.2) | 75 (2.9) | –b | –b |
| Premix insulin | –b | –b | –b | 55 (2.1) | 37 (4.4) | 8 (4.1) |
| Sulfonylurea | 978 (6.7) | 1408 (8.3) | 624 (12.2) | 435 (16.7) | 164 (19.5) | 36 (18.6) |
| SGLT2 inhibitor | 479 (3.3) | 487 (2.9) | 105 (2.1) | –b | –b | –b |
| Thiazolinedione | –b | –b | 136 (2.7) | 82 (3.1) | 24 (2.8) | –b |
| Other | 1322 (9.1) | 1545 (9.1) | 398 (7.8) | 165 (6.3) | 84 (10.0) | 13 (6.7) |
Values in table are presented as the number of patients with the percentage given in parenthesis
aChi square test examining difference in distribution of rental impairment between patients who initiate on GLP-1 RA therapy and those who initiate on an alternative GLA was statistically significant (P < 0.001)
bIndicates that < 2% of patients received this index class of therapy